With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.
2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...
Low dietary calcium might contribute to low bone mineral density (BMD) in men living with hepatitis C but not in those with HIV, according to a Veterans Administration analysis.
The majority of HIV-positive people with a statin indication by current guidelines are not receiving a statin, according to an analysis at a St. Louis HIV clinic.
Prevalence of cardiovascular disease, renal impairment and fractures or osteoporosis was higher with than without HIV every year from 2003 to 2013.
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) improved kidney and bone markers in a study focused on people 50 years old or older.
Antiretroviral therapy reduced systemic and central nervous system (CNS) inflammation in past substance users compared with nonusers, according to the results of a study presented at IDWeek 2016.
High-dose, long-term omega-3 supplementation appears to yield improved triglycerides and C-reactive protein levels among HIV-positive people who have elevated triglycerides, but only after more than a year of use, a new study has found.
Anal cancer screening was uncommon -- at only 11% -- among a study of HIV-positive men who have sex with men (MSM) receiving HIV care, despite this community being at a significantly higher risk for anal cancer, according to a study presented at IDWe...
HIV treatment as prevention has become a well-known and powerful tool in the global HIV response. In this interview, Mark Sulkowski, M.D., discusses whether a similar approach could be used in the prevention of hepatitis C.